Feedback
Settings

Settings

Goto Application

4,416 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:G16H* AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 442
1.WO/2021/247682METHODS FOR MITIGATING OR DIMINISHING SPREAD OF PATHOGENIC INFECTIONS
WO - 09.12.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
 Appl.No PCT/US2021/035421 Applicant ROSS, Peter M. Inventor ROSS, Peter M.
The present methods comprise initial administration of a first rapid test, such as rapid antigen test, that has a low likelihood of false positive results and a known likelihood of false negative results, alone or in conjunction with other rapid tests, to identify a first subpopulation of positives, to which an infection mitigation protocol (such as quarantine or the administration of a therapeutic treatment) is administered. Negatives are recorded and provisionally released from further study. A diagnostic test is then administered to this subpopulation, to identify the portion of this first subpopulation that were false positives in the first test. Ideally, a positive result for the diagnostic test is pathognomonic for the infection. Any infection mitigation protocol (such as quarantine) may then be discontinued for those testing negative in the first population and intensified for those testing positive, such as with contact tracing or other protocols, to identify all true positives and those they may have infected within the population.
2.WO/2021/237292METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION
WO - 02.12.2021
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No PCT/AU2021/050507 Applicant GENETIC TECHNOLOGIES LIMITED Inventor DITE, Gillian Sue
The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus infection.
3.2021281702Methods of assessing risk of developing a severe response to Coronavirus infection
AU - 02.12.2021
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No 2021281702 Applicant Genetic Technologies Limited Inventor ALLMAN, Richard
The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus infection.
4.3179313METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION
CA - 02.12.2021
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No 3179313 Applicant GENETIC TECHNOLOGIES LIMITED Inventor DITE, GILLIAN SUE
The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) virus infection.
5.11257569Methods of assessing risk of developing a severe response to coronavirus infection
US - 22.02.2022
Int.Class G16B 40/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
 Appl.No 17368471 Applicant GENETIC TECHNOLOGIES LIMITED Inventor Gillian Sue Dite

The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection.

6.20220246242METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION
US - 04.08.2022
Int.Class G16B 40/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
 Appl.No 17667282 Applicant GENETIC TECHNOLOGIES LIMITED Inventor Gillian Sue Dite

The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection.

7.WO/2022/174287METHODS AND SYSTEMS FOR DETECTING A CORONAVIRUS INFECTION
WO - 25.08.2022
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No PCT/AU2022/050105 Applicant COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION Inventor STEWART, Cameron
The present disclosure relates to methods, kits, and panels for determining the likelihood of a coronavirus (CoV) infection or a severe coronavirus (CoV) infection in a subject, such as a severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus infection. The disclosure also relates to methods for monitoring CoV or severe CoV infection in a subject.
8.202341003004Early Diagnosis and Preventive Mechanism for Covid19 to Cardiac Patients
IN - 20.01.2023
Int.Class A61B /
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
 Appl.No 202341003004 Applicant R.Balakrishna Inventor Dr Balakrishna R
Early Diagnosis and Preventive Mechanism for COVI19 to CARDIAC Patients proposed system will be implemented to monitor Cardiac patients and to collect the critical health parameters in order to identify the COVID-19 in its early stages. The ranges of critical parameter values are compared with the data available in the online repository. Three different levels of threshold values are used in the analysis to classify the stage 1, stage 2 and stage 3. Using three stages of analysis and threshold values preventive measures and the treatment plan is identified. The machine learning technique used in this proposed system will enhance the prediction accuracy. This system will enable quick decision making and also provides alert to the physician to give treatment in an early stage of COVID-19 and this system will support to save the life of cardiac patients in this pandemic situations.
9.20210290970ILLUMINATION DEVICES FOR INDUCING BIOLOGICAL EFFECTS
US - 23.09.2021
Int.Class A61N 5/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
5Radiation therapy
06using light
 Appl.No 17162259 Applicant KNOW Bio, LLC Inventor F. Neal Hunter

Illumination devices for impinging light on tissue, for example within a body cavity of a patient, to induce various biological effects are disclosed. Biological effects may include at least one of inactivating and/or inhibiting growth of one or more pathogens, upregulating a local immune response, increasing endogenous stores of nitric oxide, releasing nitric oxide from endogenous stores, and inducing an anti-inflammatory effect. Wavelengths of light are selected based on intended biological effects for one or more of targeted tissue types and targeted pathogens. Light treatments may provide multiple pathogenic biological effects, either with light of a single wavelength or with light having multiple wavelengths. Devices for light treatments are disclosed that provide light doses for inducing biological effects on various targeted pathogens and tissues with increased efficacy and reduced cytotoxicity. Illumination devices may be configured to communicate with networks and/or servers to provide control and/or management of phototherapy treatments.

10.20230160804Hematological Parameter for Viral Infection
US - 25.05.2023
Int.Class G01N 15/14
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
15Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
10Investigating individual particles
14Optical investigation techniques, e.g. flow cytometry
 Appl.No 17920152 Applicant Yuxiao DU Inventor Yuxiao DU

The disclosure relates to hematological parameters of viral infection. More specifically, the present disclosure relates to automated volume biomarkers lymph index and monocyte distribution width (MDW) for early detection of Coronavirus infection. The invention also relates to a method, device and computer executable program for early diagnosis of SARS-CoV-2 infection using volume biomarker lymph index and monocyte distribution width (MDW). According to some technical solutions of the present invention, the automated volumetric parameter lymph index and MDW can be used as viral biomarkers to help healthcare workers in the out-patient department or fever clinic to rapidly identify those who might be infected with SARS-CoV-2 and to provide valuable information for triage decision making.

# -